Dapagliflozin 10 mg + Metformin 1000 mg (ER) Tablets – DAPILA M 10/1000

Dapagliflozin 10 mg + Metformin 1000 mg (ER) Tablets – A robust solution for effective diabetes management.

DAPILA M 10/1000: The Dual combination of Dapagliflozin 10 mg + Metformin 1000 mg is a bilayered tablet that combines Dapagliflozin, an SGLT2 inhibitor that facilitates glucose elimination through the urine, with Metformin, which lowers blood sugar levels by decreasing glucose production in the liver and enhancing insulin action. The ER formulation of Metformin ensures prolonged glycemic control and improved patient adherence, effectively managing type 2 diabetes by addressing both fasting and postprandial glucose levels.

Recommended BY Specialists:
Endocrinologists: It is mainly used to prefer this combination to treat the disease associate with Type 2 diabetes mellitus management
General Physicians: It is preferred to treat the disease associated with first-line or second-line therapy in moderate to severe Type 2 diabetes
Cardiologists: It is mainly used to recommend in diabetic patients with cardiovascular risk factors or established heart failure (HFrEF)

Key Benefits of Dapagliflozin 10 mg + Metformin 1000 mg (ER) Tablets:
Combination of SGLT2 Inhibition and Metformin: Dapagliflozin promotes glucose excretion through the kidneys, while Metformin improves insulin sensitivity and reduces hepatic glucose production, providing synergistic effects on blood sugar control.
Sustained Release Formulation: The extended release (ER) technology allows for gradual absorption of Metformin, minimizing gastrointestinal side effects and ensuring consistent blood glucose levels throughout the day.
Cardiovascular and Renal Benefits: Dapagliflozin is associated with cardiovascular protection and renal health improvements, making this combination suitable for patients with additional cardiovascular risk factors

INDICATIONS:
Type 2 Diabetes Mellitus
Inadequate glycemic control
T2DM with CVD